Influenza virus hemagglutinin mutants
AssigneeAramis Biotechnologies Inc.
InventorsPierre-Olivier LAVOIE, Aurelien LORIN, Alain DOUCET, Marc-Andre D'AOUST, Manon COUTURE
Life of this patent
Estimating the term…
Loading patent…
AssigneeAramis Biotechnologies Inc.
InventorsPierre-Olivier LAVOIE, Aurelien LORIN, Alain DOUCET, Marc-Andre D'AOUST, Manon COUTURE
Estimating the term…
The present invention relates to the production of modified influenza viral proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.
A modified influenza H3 hemagglutinin (HA) protein comprising an amino acid sequence of a wildtype influenza H3 HA protein and comprising at least one amino acid substitution, said at least one amino acid substitution consisting of an amino acid substitution corresponding to position 382 of reference sequence SEQ ID NO:
Dependencies are inferred from the claim text.